PMID- 23107893
OWN - NLM
STAT- MEDLINE
DCOM- 20130516
LR  - 20211203
IS  - 1878-7436 (Electronic)
IS  - 1878-7436 (Linking)
VI  - 6
IP  - 6
DP  - 2012 Nov-Dec
TI  - Inhibition of MCP-1/CCR2 signaling pathway is involved in synergistic inhibitory 
      effects of irbesartan with rosuvastatin on vascular remodeling.
PG  - 375-84
LID - S1933-1711(12)00247-1 [pii]
LID - 10.1016/j.jash.2012.10.002 [doi]
AB  - Additional beneficial effects of angiotensin II type 1 (AT(1)) receptor blockers 
      beyond AT(1) receptor blockade have been highlighted. Irbesartan is reported to 
      act as an antagonist of the monocyte chemoattractant protein-1 (MCP-1) receptor, 
      C-C chemokine receptor 2 (CCR2). We examined the possible synergistic effects of 
      the combination of irbesartan with rosuvastatin on preventing vascular remodeling 
      focusing on the MCP-1/CCR2 pathway. We observed that administration of irbesartan 
      and CCR2 antagonist, propagermanium, at noneffective doses, decreased the 
      neointima with a decrease in PCNA labeling index in the injured mouse femoral 
      artery induced by cuff placement. We also observed that administration of a 
      noneffective dose of rosuvastatin with propagermanium decreased the neointima 
      area, suggesting that the inhibitory effect of rosuvastatin on neointima 
      formation is at least partly attributable to blockade of the MCP-1/CCR2 pathway. 
      Moreover, we demonstrated that the combination of irbesartan with rosuvastatin 
      decreased neointima formation. MCP-1 mRNA level was significantly increased in 
      injured femoral arteries, and administration of irbesartan with rosuvastatin 
      decreased the mRNA levels of MCP-1, TNFalpha, and IL-1beta, and increased PPARgamma mRNA 
      expression. These results suggest that the synergistic inhibitory effects of 
      irbesartan with rosuvastatin on neointima formation may involve attenuation of 
      MCP-1/CCR2 signaling.
CI  - Copyright (c) 2012 American Society of Hypertension. Published by Elsevier Inc. All 
      rights reserved.
FAU - Ohshima, Kousei
AU  - Ohshima K
AD  - Department of Molecular Cardiovascular Biology and Pharmacology, Ehime 
      University, Graduate School of Medicine, Tohon, Ehime, Japan.
FAU - Mogi, Masaki
AU  - Mogi M
FAU - Nakaoka, Hirotomo
AU  - Nakaoka H
FAU - Jing, Fei
AU  - Jing F
FAU - Iwanami, Jun
AU  - Iwanami J
FAU - Min, Li-Juan
AU  - Min LJ
FAU - Tsukuda, Kana
AU  - Tsukuda K
FAU - Kanno, Harumi
AU  - Kanno H
FAU - Ogimoto, Akiyoshi
AU  - Ogimoto A
FAU - Higaki, Jitsuo
AU  - Higaki J
FAU - Horiuchi, Masatsugu
AU  - Horiuchi M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121026
PL  - United States
TA  - J Am Soc Hypertens
JT  - Journal of the American Society of Hypertension : JASH
JID - 101312518
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Fluorobenzenes)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Propionates)
RN  - 0 (Pyrimidines)
RN  - 0 (Receptors, CCR2)
RN  - 0 (Sulfonamides)
RN  - 0 (Tetrazoles)
RN  - 00072J7XWS (Germanium)
RN  - 1Q2P9TO9Q7 (propagermanium)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - J0E2756Z7N (Irbesartan)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/pharmacology
MH  - Animals
MH  - Biphenyl Compounds/*pharmacology
MH  - Chemokine CCL2/*drug effects
MH  - Drug Synergism
MH  - Femoral Artery/*drug effects/injuries/pathology
MH  - Fluorobenzenes/*pharmacology
MH  - Germanium
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology
MH  - Irbesartan
MH  - Mice
MH  - Neointima/pathology/prevention & control
MH  - Organometallic Compounds/pharmacology
MH  - Propionates
MH  - Pyrimidines/*pharmacology
MH  - Receptors, CCR2/*drug effects
MH  - Rosuvastatin Calcium
MH  - Signal Transduction/*drug effects
MH  - Sulfonamides/*pharmacology
MH  - Tetrazoles/*pharmacology
EDAT- 2012/10/31 06:00
MHDA- 2013/05/17 06:00
CRDT- 2012/10/31 06:00
PHST- 2012/07/26 00:00 [received]
PHST- 2012/09/15 00:00 [revised]
PHST- 2012/10/01 00:00 [accepted]
PHST- 2012/10/31 06:00 [entrez]
PHST- 2012/10/31 06:00 [pubmed]
PHST- 2013/05/17 06:00 [medline]
AID - S1933-1711(12)00247-1 [pii]
AID - 10.1016/j.jash.2012.10.002 [doi]
PST - ppublish
SO  - J Am Soc Hypertens. 2012 Nov-Dec;6(6):375-84. doi: 10.1016/j.jash.2012.10.002. 
      Epub 2012 Oct 26.